Ribociclib (Kisqali) 200mg*21's | Novartis Taiwan, China | GLT

Generic Information: Kisqali (Taiwan, China)

Kisqali is the originator brand of ribociclib, developed and marketed worldwide by Novartis. This Taiwan-sourced presentation comes as a pack of 21 film-coated tablets, each containing 200 mg of ribociclib. Ribociclib is an oral CDK4/6 inhibitor used together with endocrine therapy to treat hormone-receptor-positive, HER2-negative breast cancer, and it has been approved and made available to patients in Taiwan.

What Is Ribociclib (Kisqali) Used For?

Ribociclib is used to treat HR-positive, HER2-negative breast cancer. In advanced or metastatic disease it is given in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant. It is also approved for the adjuvant treatment of adults with HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence. In every setting, ribociclib works together with hormone therapy rather than as a standalone treatment.

How Does Ribociclib Work?

Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These enzymes control the checkpoint that allows cells to move from the G1 phase into the DNA-synthesis (S) phase of the cell cycle. In HR-positive breast cancer, tumour cells depend heavily on CDK4/6 signalling to keep dividing. By blocking CDK4 and CDK6, ribociclib arrests cancer cells at this checkpoint and slows tumour growth, which is why it is combined with hormone therapy that targets the oestrogen-driven growth signals in parallel.

Indications

The approved indications are HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, and HR-positive, HER2-negative stage II/III early breast cancer at high risk of recurrence as adjuvant therapy. Treatment should be initiated and supervised by an oncologist experienced in breast-cancer management, and hormone-receptor and HER2 status must be confirmed before starting.

Dosage

The recommended starting dose for advanced or metastatic disease is 600 mg, taken as three 200 mg tablets once daily with or without food. Treatment follows a 28-day cycle of 21 days on therapy followed by 7 days off. A 21-tablet pack therefore covers one week at the 600 mg daily dose. For early breast cancer the starting dose is 400 mg (two tablets) daily. Dose reductions to 400 mg or 200 mg daily are used to manage side effects such as neutropenia or liver-enzyme elevations.

Side Effects

The most common side effects are neutropenia, nausea, fatigue, diarrhoea, vomiting, hair loss, headache and constipation. Important but less frequent effects include QT-interval prolongation on the ECG, liver toxicity, interstitial lung disease and, rarely, severe skin reactions. Blood counts, liver function, electrolytes and the ECG are monitored regularly, and patients should report fever, persistent diarrhoea, yellowing of the skin or new breathing difficulty promptly.

Storage

Store Kisqali tablets at room temperature in the original container, protected from moisture, and out of the reach of children. Do not use past the expiry date shown on the pack.

Why Choose Kisqali Through GLT?

For overseas patients and institutions, sourcing ribociclib through GLT provides access to a genuine Novartis originator product from a choice of markets. We help patients and institutions compare originator and licensed generic options so they can balance brand preference against cost, and we ship from a Hong Kong-licensed facility with transparent documentation.

How to Order

To order Kisqali (ribociclib) from GLT, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. We will confirm current availability, pricing and delivery to your country, and we ship from a Hong Kong-licensed facility.

FAQ

How many tablets do I take each day? For advanced or metastatic breast cancer, the standard dose is three 200 mg tablets (600 mg) once daily for 21 days, followed by a 7-day break in each 28-day cycle.

How long does a 21-tablet pack last? At the standard 600 mg daily dose, one pack covers seven days of the active-treatment phase.

Is ribociclib used alone? No — it is always combined with an aromatase inhibitor or fulvestrant as part of endocrine therapy.